 AstraZeneca PLC LSE:AZN was a rare riser in the FTSE 100 after it said today it had received two recommendations for drug approvals in the EU, while a drug for blood disorder paroxysmal nocturnal haemoglobinuria met its primary endpoint in a phase three trial. The group said its Beyfortus drug, which it develops with Sanofi. 